# Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?

> **NCT03636763** · — · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 183 (estimated)

## Conditions studied

- Bullous Pemphigoid

## Interventions

- **DRUG:** data report

## Key facts

- **NCT ID:** NCT03636763
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09
- **Primary completion:** 2019-03
- **Final completion:** 2019-12
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636763, "Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03636763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*